Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
A message from Hikma CEO Riad Mishlawi
![Decorative image.](/media/tnwj5bxg/riad-large-banner.jpg?width=1792&height=900&v=133517223228800000&format=webp)
Latest stories
Featured
Hikma delivers strong 2023 performance and a positive outlook for 2024
Press Release, Financial Results 22 February 2024
- Hikma Pharmaceuticals USA Inc. Extends Voluntary Nationwide Recall of One Lot of Acetaminophen Injection, 1000mg/100mL, (10mg/mL) Bags Due to an Individual Unit of Acetaminophen Overwrap Found to Have Contained a Labelled Bag of Dexmedetomidine HCL Injection (400mcg/100mL) Press Release, Product 22 July 2024 Hikma Pharmaceuticals USA Inc. Extends Voluntary Nationwide Recall of One Lot of Acetaminophen Injection, 1000mg/100mL, (10mg/mL) Bags Due to an Individual Unit of Acetaminophen Overwrap Found to Have Contained a Labelled Bag of Dexmedetomidine HCL Injection (400mcg/100mL)
- Hikma Pharmaceuticals Receives Permanent J-Code for COMBOGESIC® IV (acetaminophen and ibuprofen) injection from Centers for Medicare & Medicaid Services (CMS) Press Release, Product 16 July 2024 Hikma Pharmaceuticals Receives Permanent J-Code for COMBOGESIC® IV (acetaminophen and ibuprofen) injection from Centers for Medicare & Medicaid Services (CMS)
- Notice of results Press Release, Corporate 15 July 2024 Notice of results
- Hikma launches Sodium Acetate Injection, USP, in the US Press Release, Product 11 July 2024 Hikma launches Sodium Acetate Injection, USP, in the US